Deep Brain Stimulation in Patients With Dystonia

Dystonia Clinical Trial

— STN DBS  

Official title:

Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Patients With Dystonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00773604
• Other study ID #: Private donor
• Status: Completed
• Phase: N/A
• Start date: June 2008
• Est. completion date: February 2015

Study information

• Verified date: February 2019
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation (DBS) of the subthalamic nucleus (STN)for primary dystonia.

Description:

Dystonia is an uncommon brain disorder in which there is abnormal muscle tone producing twisting, writhing movements and abnormal postures. It is associated with abnormal electrical activity in two groups of nerve cells in the brain called the globus pallidus internus (GPi) and the subthalamic nucleus (STN). Deep brain stimulation (DBS) has been shown to be an effective treatment in patients with medically refractory dystonia and is currently approved for both the GPi and STN targets under a humanitarian device exemption (HDE) for use in segmental and generalized primary dystonia as well as focal cervical dystonia. GPi DBS appears to be effective for medication-refractory focal and segmental dystonia affecting the cranial and cervical regions in open-label series, but recently GPi stimulation has been associated with subtle motor disturbances in previously non-dystonic body regions (i.e., arms and legs) in this population of patients. DBS of the STN has also been reported to be effective for treating generalized and cervical dystonia in small open label trials. STN DBS for cranial and cervical regions may provide similar efficacy in the treatment of dystonia as GPi DBS, but without unwanted stimulation-induced motor effects. Objectives of this study are to evaluate the safety and efficacy of STN DBS for dystonia. Up to twenty-five patients will be screened, consented, and enrolled in this study. All patients will undergo bilateral STN DBS for dystonia. Participants will be evaluated pre- and postoperatively with standard dystonia rating scale Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and a patient questionnaire will be administered postoperatively to determine if patients are experiencing stimulation-induced motor adverse effects and will be logged for safety monitoring. This pilot study will provide preliminary open label efficacy outcomes for STN DBS in the treatment of primary dystonia and will help determine if this target should be compared to GPi DBS in a larger double-blind trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 80 Years

Eligibility

Inclusion Criteria:

• Refractory primary dystonia diagnosed by a movement disorders neurologist

• Severe functional impairment despite optimal medical management, including failed botulinum toxin therapy

• Age 7-80 years (UCSF patients) and 18-80 (VA patients)

Exclusion Criteria:

• Patients considered at high risk for elective neurosurgery because of co-morbid conditions

• Brain MRI showing extensive brain atrophy or small vessel ischemic disease

• Pregnancy

• Inability to tolerate awake microelectrode-guided neurosurgery

• Inability to follow up with post-operative study visits

• Inability to speak or read English

• Patients with a score of 4.5 or lower on the BFMDRS movement scale

• Patients with Secondary dystonia

Related Conditions & MeSH terms

• Dystonia
• Dystonic Disorders

Intervention

Device:
• Medtronic implantable deep brain stimulation (DBS) system
surgical placement of deep brain stimulation system for treatment of dystonia

Locations

Country	Name	City	State
United States	San Francisco Veterans Administration Medical Center	San Francisco	California
United States	University of California, San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months	Total TWSTRS score range is 0-88, where higher score indicates worse symptoms. Values are calculated by baseline minus 12 month, where higher difference score of change between baseline and 12 months means better outcome (more improvement)	Baseline and 12 months